Although the literature concerning 1-hydrazinophthalazine (Hydralazine) contains many reports of its effects on arterial blood pressure, its relation to various vasomotor reflexes and autonomic blocking agents (1-4), as well as detailed studies of its pharmacological action in animals (5-7), information concerning hemodynamic effects in subjects having essential arterial hypertension is incomplete. The present report concerns various hemodynamic observations in 17 hypertensive patients to whom Hydralazine was administered intravenously.
MATERIAL AND METHODS
This study was done on 17 postabsorptive subjects chosen from the general medical wards. The clinical diagnosis in each case was essential hypertension, although one patient (No. 15) had, in addition, old chronic pyelonephritis involving the lower half of the left kidney. None of these patients was in cardiac decompensation clinically or as measured by the central venous pressure at the time of study. Special effort was made to secure basal conditions by maintaining as much comfort as possible and by explaining the procedure to the patient prior to the day of catheterization and again prior to each step of the procedure. One member of the team tried to establish rapport with each patient during the study by engaging him or her in light conversation about a non-medical subject, preferably one of the subject's choosing.
Cardiac output was determined in the supine position by means of the Fick principle. This was accomplished by placing a cardiac catheter in the pulmonary artery and an indwelling needle in a peripheral artery, usually the femoral. Expired Table I was given through the cardiac catheter into the pulmonary artery. The blood pressure was then observed by continuous inspection of the arterial pressure tracing until it had decreased and stabilized at its new level for at least 10 minutes. An average of 43 minutes elapsed following drug administration before the second cardiac output was determined. During this time some of the subjects had cerebral, some coronary, and some renal hemodynamic studies.
RESULTS
The results are shown in Table I . They are divided into two groups because of the marked yet unpredictable difference in response. Twelve patients, called Group One, experienced mild nasal obstruction, cutaneous facial flushing, and palpitation but no particular discomfort. Five subjects, called Group Two, experienced an adverse reaction characterized by a marked fall in blood pressure, pallor, apprehension, diaphoresis, nausea, and frequently emesis. When this occurred, 100 per cent 02 was given by mask to produce relief of the patient's discomfort and a rise in blood pressure. In these cases the determination of the second cardiac output was delayed until the blood pressure was stable and symptoms were absent.
One patient (No. 16) had a blood pressure fall from a mean of 173 to 24 mm. Hg accompanied by nodal bradycardia. He was given 02 by mask, then methoxamine 2 mg. intravenously, followed by 12 mg. intramuscularly, to maintain his pressure high enough for the second output. The data derived from this study would have been omitted from the report except that his response is similar to the rest of those in Group Two. The average dose of Hydralazine was the same in both groups.
+3% -52% -40% -45% -33% +3% ---------------------------------------------------------------
The cardiac rate in Group One increased from a mean in the control period of 83 beats per minute to a mean of 102 beats per minute (p < 0.01) after the intravenous administration of Hydralazine. In Group Two, who had marked hypotension, no increase in pulse rate occurred, and in two cases (No. 15 Peripheral arterial resistance was reduced by 31 per cent (p < 0.01) in Group One and 52 per cent in Group Two (p < 0.05), whereas total pulmonary resistance fell by 28 per cent (p < 0.02) and 40 per cent (p < 0.2), respectively, in the two groups. With the concomitant fall in peripheral arterial blood pressure and the change in cardiac output, cardiac work against pressure fluctuated unpredictably. The left ventricular work fell in Group Two (-45 per cent, p < 0.02) and right ventricular work rose in Group One (p < 0.05).
In Group One 02 consumption and arterial 02 level were not significantly changed by Hydralazine. The increased cardiac output produced a decrease in arteriovenous 02 difference (p < 0.01) because of the increase in the mean mixed venous 02 content of 1.0 volume per 100 cc. By contrast, in Group Two there was a fall in arterial 02 content (p < 0.02). Here the variability of mixed venous 02 was such that no statistically significant change occurred in the arteriovenous 02 difference. Oxygen consumption remained the same.
In 10 patients of Group One the minute volume of respiration increased after the administration of Hydralazine, the average increase for the entire group being 21 per cent (p < 0.05). As would be expected in these circumstances, the arterial CO2, mixed venous CO2 and arterio-mixed venous CO2 difference all decreased (p < 0.01). In Group Two the arterial and venous blood CO2 content changes were similar but less significant, probably because of the smaller number of patients. Constant CO2 production and unchanged respiratory quotients of both groups attested to the attainment of a reasonably steady state by the time of the second hemodynamic determinations.
DISCUSSION
A previous report of cardiac output after administration of Hydralazine was made by Wilkinson, Backman, and Hecht (11) The data from Group One suggest that the primary change after administration of Hydralazine to these patients with hypertension is a decrease in the vascular resistance both in the systemic cir-culation (-31 per cent) and in the lung (-28 per cent). Accompanying this decrease in vascular resistance there is a fall in systemic arterial pressure (-17 per cent) and a rise in cardiac output (+ 33 per cent). In spite of the increase in cardiac output, calculated left ventricular pressure work is not increased and the 02 consumption remains essentially the same. It seems clear that the vasodilatation produced by this drug is quite general since it is found in cerebral (15, 16) , hepatic (7, 14) , renal (11, 17) , and coronary vascular beds (18) as well as in the systemic and pulmonary vascular beds as a whole as shown in this study. However, the degree of vasodilatation is not the same in all areas (11, 18) . Skin temperature was not found to increase generally by Wilkinson, Backman, and Hecht but did occur locally after direct intra-arterial administration (11) . It was shown to rise in local areas after intravenous administration in pregnant patients by Assali, Kaplan, Oighenstein, and Suyemoto (12) .
The changes produced in Group Two were complicated by the precipitation of marked hypotension and the resulting adjustments which occur secondary to such a hemodynamic condition. It seems probable that this marked hypotensive effect was due to failure of venous return because of peripheral and splanchnic pooling of blood. This cannot be stated with certainty, since the central venous pressure was measured at the beginning and end of the procedure, not during the most hypotensive phase. The slight fall in arterial 02 content appears related to the marked hypotensive phase.
A mild degree of hyperventilation occurred in both groups as shown by the increase in minute volume of respiration, and further manifested by the fall in arterial and venous CO2 contents. Although pH determinations were not done in this study, arterial pH as determined by Hafkenschiel and his associates (15) showed a slight rise after administration of Hydralazine. The reason for this hyperventilation is not known, but the fact that it was less in the Group Two patients, who were most apprehensive and uncomfortable, suggests that it was not psychogenic.
During the study and in retrospect since its completion an attempt has been made to determine what factor or factors accounted for the different response of Group One and Group Two. Statistical testing indicates that Group Two patients had, on the average, higher mean arterial blood pressure (p < 0.02), lower stroke index (p < 0.05), and lower 02 consumption per liter ventilation (p < 0.05) than Group One patients. None of the other factors which we measured could be shown statistically to be related to the difference in response. It is interesting to speculate that the response to 1-hydrazinophthalazine may be related to cardiac reserve. The increase in cardiac output of normal patients (Wilkinson, Backman, and Hecht) was 112 per cent, our Group One hypertensive subjects had only a 33 per cent increase and the Group Two hypertensive subjects, with an even higher arterial blood pressure, showed no significant change. Other patients in Group One who did not experience adverse symptoms but who had severe hypertension, e.g., No. 4, or a very low initial cardiac output, as No. 10, also had no increase in cardiac output after the drug was given. This suggests that there is a continuous spectrum of response from the patient who becomes flushed and warm, develops tachycardia, and increases his cardiac output and left ventricular work to the patient who develops marked hypotension, pallor, sweating, apprehension, bradycardia with nodal rhythm, and whose cardiac output and cardiac work fall. CONCLUSIONS 1. Administration of 1-hydrazinophthalazine intravenously to 17 subjects with arterial hypertension produced a decrease in peripheral and pulmonary vascular resistance with a decrease in systemic arterial blood pressure accompanied generally by increased cardiac output. However, when severe hypotension occurred, cardiac output remained the same or fell.
2. Left ventricular work fell when marked hypotension occurred, but otherwise was unchanged.
3. Hyperventilation occurred after Hydralazine administration in 14 of 17 patients with a fall in arterial and mixed venous CO2 and a decrease in arteriovenous CO2 difference.
4. No significant change occurred in 02 consumption, total CO2 production, or respiratory quotient.
